Skip to main content
. 2015 Dec 15;8(12):22117–22128.

Figure 3.

Figure 3

Pooled relative risk in the improvement of dyspnea (A), edema (B), pulmonary rales (C), pulmonary congestion (D) in the studies considering tolvaptan compared to placebo therapy in HF patients. The results indicated a statistical significance in the improvement of dyspnea (RR=1.10, 95% CI=1.07 to 1.13, P<0.001) and edema (RR=1.05, 95% CI=1.02 to 1.08, P<0.001), whereas there were no significant differences in the improvement of pulmonary rales (RR=2.38, 95% CI=0.89 to 6.38, P=0.08) and pulmonary congestion (RR=1.02, 95% CI=0.71 to 1.45, P=0.93).